Theranostic in early detection of recurring prostate cancer: <sup>64</sup>CuCl<sub>2</sub> — ASN Events
  1. Schedule
  2. A New Era of Prostate Cancer Imaging - (submitted abstract)
  3. Theranostic in early detection of recurring prostate cancer: 64CuCl2

Theranostic in early detection of recurring prostate cancer: 64CuCl2 (#29)

Gianluca Valentini 1 , Paola Panichelli 1 , Gioia Pigotti 1 , Beatrice Giacobbi 1 , Domenico Martini 1 , Giulio Milanese 2 , Paolo Mengoni 3
  1. A.C.O.M. SrL, Montecosaro , Italy
  2. Chair of Urological and Andrological Sciences, Università Politecnica delle Marche, Ancona, Italy
  3. Urology, ASL - San Benedetto del Tronto, San Benedetto del Tronto, Italy

AIM:to evaluate the use of PET/CT with 64CuCl2 in recurring prostate cancer after surgery in patients with low PSA level (<2). 

INTRODUCTION:Previous works* demonstrated as 64CuCl2 is a PET probe in prostate cancer in mice with xenografts of prostate cancer.Moreover, it was described** in seven patients the role of 64CuCl2 PET/CT in staging of prostate cancer.

METHOD:32 Patients with low PSA level (<2) in recurring prostate post -surgical cancer were studied with 64CuCl2 PET/CT executed at 1h,3h and 24h after injection of 200-400 MBq (medium activity 4 MBq/kg). A dosimetric analysis was done with manual VOI on various organs(Liver,Kidneys,Spleen,lumbar spine L4-L5 and Prostate as target). Coregistered  imaging with CT to calculate VOIs, specific activity (Bq/ml) and SUVmax  were executed. We analyzed time/activity curve with Olinda /EXM software to calculate absorbed dose. All patients had a control of PSA 10 days after PET/CT scan.

RESULTS:the PSA value was 1.1 ng/ml(0,4-1,9 ng/ml). All patients showed lesions with an uptake of 64CuCl2 with a ratio lesion/background grate than 10. The positive lesions (n=63) had a medium dimension of 5.2 mm (3-9 mm) in linfonodes (n=46),Prostatic lodge (n=13) and Bone (n=4). After 10 days all patients presented a reduction of PSA with a medium of 0.3 ng/ml (0.1-0.5). Sensibility 90%.

CONCLUSION:PET/CT scan with 64CuCl2 is a high sensitivity method to detect early recurring prostate cancer after surgery. The possibility to see the lesions in early stage and in low dimensions (3-9 mm) opens a new possibility for theranostic application. The reduction value of PSA after 10 days could be related to the therapeutic effect of 64CuCl2. When the lesions are very small, a diagnostic dose could be also therapeutic. Further studies are necessary, but this could be a new approach in theranostic application.

 *F.Peng et Al. - J.Nucl.Med. 2006; **E.Capasso et Al. - Ann.Nucl.Med. 2015